Ghaith Abu-Zeinah

List of Publications by Year
in descending order

22 papers	406 citations	1307594 7 h-index	839539 18 g-index
24 all docs	24 docs citations	24 times ranked	757 citing authors

#	Article	IF	Citations
1	Excess mortality in younger patients with myeloproliferative neoplasms. Leukemia and Lymphoma, 2023, 64, 725-729.	1.3	5
2	Normal life expectancy for polycythemia vera (PV)Âpatients is possible. Leukemia, 2022, 36, 569-572.	7.2	16
3	Hematopoietic fitness of <i>JAK2V617F</i> myeloproliferative neoplasms is linked to clinical outcome. Blood Advances, 2022, 6, 5477-5481.	5.2	4
4	Outcomes in <scp>CLL</scp> patients with <scp><i>NOTCH1</i></scp> regulatory pathway mutations. American Journal of Hematology, 2021, 96, E187-E189.	4.1	4
5	Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leukemia, 2021, 35, 2592-2601.	7.2	52
6	A Novel Machine Learning-Derived Dynamic Scoring System Predicts Risk of Thrombosis in Polycythemia Vera (PV) Patients. Blood, 2021, 138, 3619-3619.	1.4	2
7	Excess Mortality in Young Patients with Myeloproliferative Neoplasms. Blood, 2021, 138, 235-235.	1.4	6
8	Hematopoietic Stem and Progenitor Cell Fitness As a Novel Prognostic and Monitoring Biomarker for <i>JAK2 V617F</i> Myeloproliferative Neoplasms (MPNs). Blood, 2021, 138, 627-627.	1.4	1
9	Normal Life Expectancy for Polycythemia Vera Patients Is Possible. Blood, 2021, 138, 2575-2575.	1.4	1
10	Splenomegaly (SPML) in Polycythemia Vera (PV): Its Clinical Significance and Relation to Myelofibrosis and Survival. Blood, 2021, 138, 2580-2580.	1.4	0
11	Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics. Blood, 2021, 138, 2583-2583.	1.4	1
12	<p>Understanding Sideroblastic Anemia: An Overview of Genetics, Epidemiology, Pathophysiology and Current Therapeutic Options</p>. Journal of Blood Medicine, 2020, Volume 11, 305-318.	1.7	23
13	Megakaryocyte TGFÎ²1 partitions erythropoiesis into immature progenitor/stem cells and maturing precursors. Blood, 2020, 136, 1044-1054.	1.4	11
14	Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival. Blood, 2020, 136, 31-32.	1.4	4
15	Somatic mutations and cell identity linked by Genotyping of Transcriptomes. Nature, 2019, 571, 355-360.	27.8	206
16	Thrombotic risk factors in patients with antiphospholipid syndrome: a single center experience. Journal of Thrombosis and Thrombolysis, 2019, 48, 233-239.	2.1	10
17	Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 50-58.	4.9	41
18	Myeloproliferative Neoplasm (MPN) Driver Mutations Are Enriched during Hematopoietic Stem Cell Differentiation in Patterns That Correlate with Clinical Phenotype and Treatment Response. Blood, 2018, 132, 4317-4317.	1.4	2

#	Article	IF	Citations
19	Initial Therapy of Polycythemia Vera (PV) with Interferon Alfa (rIFNa) Compared to Hydroxyurea (HU) or Phlebotomy Only (PHL-O) Is Associated with a Lower Risk of Secondary Myelofibrosis. Blood, 2018, 132, 4316-4316.	1.4	0
20	Acute myeloid leukemia masquerading as hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2016, 7, E31-E35.	1.4	6
21	Diaphragmatic Amyloidosis Causing Respiratory Failure: A Case Report and Review of Literature. Case Reports in Oncological Medicine, 2015, 2015, 1-4.	0.3	1
22	From the liver to the foot: a case of systemic embolism and acrometastasis in hepatocellular carcinoma. Gastrointestinal Cancer Research: GCR, 2014, 7, 103-7.	0.7	2